These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 11795366)

  • 1. Raloxifene: risks and benefits.
    Barrett-Connor E
    Ann N Y Acad Sci; 2001 Dec; 949():295-303. PubMed ID: 11795366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
    Hadji P
    Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A; Adachi JD
    Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.
    Cohen FJ; Lu Y
    Maturitas; 2000 Jan; 34(1):65-73. PubMed ID: 10687884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability profile of SERMs.
    Agnusdei D; Iori N
    J Endocrinol Invest; 1999 Sep; 22(8):641-5. PubMed ID: 10532252
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene hydrochloride.
    Snyder KR; Sparano N; Malinowski JM
    Am J Health Syst Pharm; 2000 Sep; 57(18):1669-75; quiz 1676-8. PubMed ID: 11006795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
    Ko SS; Jordan VC
    Expert Opin Pharmacother; 2011 Mar; 12(4):657-74. PubMed ID: 21294695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
    Calaf Alsina J; Coronado Martín PJ
    Med Clin (Barc); 2013 Mar; 140(6):266-71. PubMed ID: 23276611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of SERMs on the uterus and menopausal symptoms.
    Dören M
    J Endocrinol Invest; 1999 Sep; 22(8):625-35. PubMed ID: 10532250
    [No Abstract]   [Full Text] [Related]  

  • 15. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist].
    Chmel R; Rob L; Strnad P
    Ceska Gynekol; 2002 Jul; 67(4):187-91. PubMed ID: 12373918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene: a review of its use in the prevention of invasive breast cancer.
    Moen MD; Keating GM
    Drugs; 2008; 68(14):2059-83. PubMed ID: 18778124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raloxifene for older women: a review of the literature.
    Hansdóttir H
    Clin Interv Aging; 2008; 3(1):45-50. PubMed ID: 18488877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health.
    Draper MW
    Ann N Y Acad Sci; 2003 Nov; 997():373-7. PubMed ID: 14644844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on raloxifene to prevent endometrial-breast cancer.
    Goldstein SR
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S54-6. PubMed ID: 11056320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.